Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation: 2014-2025

Historic Share-based Compensation for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to $11.2 million.

  • Viridian Therapeutics, Inc.\DE's Share-based Compensation rose 29.01% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.3 million, marking a year-over-year decrease of 30.28%. This contributed to the annual value of $42.1 million for FY2024, which is 37.25% down from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Share-based Compensation is $11.2 million, which was up 3.74% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Share-based Compensation registered a high of $26.0 million during Q4 2023, and its lowest value of $3.2 million during Q1 2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Share-based Compensation averaged around $12.9 million, with its median value being $11.8 million (2024).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Share-based Compensation surged by 547.48% in 2021 and then crashed by 65.54% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Share-based Compensation (Quarterly) stood at $3.5 million in 2021, then skyrocketed by 51.19% to $5.3 million in 2022, then soared by 393.52% to $26.0 million in 2023, then tumbled by 65.54% to $9.0 million in 2024, then climbed by 29.01% to $11.2 million in 2025.
  • Its Share-based Compensation was $11.2 million in Q3 2025, compared to $10.8 million in Q2 2025 and $10.2 million in Q1 2025.